MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency

Mehran Ghaderi, Giovanni Gambelunghe, Cristina Tortoioli, Annalisa Brozzetti, Ken Jatta, Baback Gharizadeh, Annamaria De Bellis, Francesca Pecori Giraldi, Massimo Terzolo, Corrado Betterle, Alberto Falorni

Research output: Contribution to journalArticle

Abstract

Context: The polymorphism of class II HLA genes modulates the genetic risk for several endocrine autoimmune diseases. The constitutive class II expression on antigen-presenting cells is under the control of the MHC class II transactivator, encoded by the MHC2TA gene, which is mapped to chromosome 16p13. The MHC2TA -168 A→G single nucleotide polymorphism (rs3087456) has been suggested to confer susceptibility to some autoimmune diseases. Design: With the aim of testing whether this MHC2TA single nucleotide polymorphism is independently associated with autoimmune Addison's disease (AAD) and/or modulates the genetic risk conferred by DRB1-DQA1-DQB1 haplotypes, we analyzed DNA samples from 128 AAD patients and 406 healthy control subjects from continental Italy. Results: Frequency of allele G of MHC2TA was significantly increased among AAD patients (39% alleles), compared with 29% in healthy controls (P = 0.003). Similarly, the frequency of AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a codominant (P = 0.012) and a G-dominant model (P = 0.018). Multivariate logistic regression analysis showed that MHC2TA AG+GG continued to be positively associated with genetic risk for AAD (P = 0.028, odds ratio = 1.72, 95% confidence interval = 1.06-2.78), after correction for DRB1*03- DQA1*0501-DQB1*0201, DRB1*04 (not 0403)-DQA1*0301- DQB1*0302 and DRB1*0403. Similar results were obtained when the number of G alleles was included in the model (P = 0.004; odds ratio = 1.65, 95% confidence interval = 1.17-2.32). Conclusions: Our study provides the first demonstration of the association of the polymorphism of the MHC2TA gene with genetic risk for AAD that appears to be independent from the well-known association with the polymorphism of HLA class II genes.

Original languageEnglish
Pages (from-to)4107-4111
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number10
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Adrenal Insufficiency
Polymorphism
Addison Disease
Autoimmune Diseases
Single Nucleotide Polymorphism
Nucleotides
Genes
MHC Class II Genes
Healthy Volunteers
Alleles
Odds Ratio
Confidence Intervals
Endocrine System Diseases
Antigen-Presenting Cells
Chromosomes
Gene Frequency
Regression analysis
Haplotypes
Italy
Logistics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Ghaderi, M., Gambelunghe, G., Tortoioli, C., Brozzetti, A., Jatta, K., Gharizadeh, B., ... Falorni, A. (2006). MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. Journal of Clinical Endocrinology and Metabolism, 91(10), 4107-4111. https://doi.org/10.1210/jc.2006-0855

MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. / Ghaderi, Mehran; Gambelunghe, Giovanni; Tortoioli, Cristina; Brozzetti, Annalisa; Jatta, Ken; Gharizadeh, Baback; De Bellis, Annamaria; Giraldi, Francesca Pecori; Terzolo, Massimo; Betterle, Corrado; Falorni, Alberto.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 10, 10.2006, p. 4107-4111.

Research output: Contribution to journalArticle

Ghaderi, M, Gambelunghe, G, Tortoioli, C, Brozzetti, A, Jatta, K, Gharizadeh, B, De Bellis, A, Giraldi, FP, Terzolo, M, Betterle, C & Falorni, A 2006, 'MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency', Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4107-4111. https://doi.org/10.1210/jc.2006-0855
Ghaderi, Mehran ; Gambelunghe, Giovanni ; Tortoioli, Cristina ; Brozzetti, Annalisa ; Jatta, Ken ; Gharizadeh, Baback ; De Bellis, Annamaria ; Giraldi, Francesca Pecori ; Terzolo, Massimo ; Betterle, Corrado ; Falorni, Alberto. / MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 10. pp. 4107-4111.
@article{e58d90d402184fa1a082fb06e9f9651a,
title = "MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency",
abstract = "Context: The polymorphism of class II HLA genes modulates the genetic risk for several endocrine autoimmune diseases. The constitutive class II expression on antigen-presenting cells is under the control of the MHC class II transactivator, encoded by the MHC2TA gene, which is mapped to chromosome 16p13. The MHC2TA -168 A→G single nucleotide polymorphism (rs3087456) has been suggested to confer susceptibility to some autoimmune diseases. Design: With the aim of testing whether this MHC2TA single nucleotide polymorphism is independently associated with autoimmune Addison's disease (AAD) and/or modulates the genetic risk conferred by DRB1-DQA1-DQB1 haplotypes, we analyzed DNA samples from 128 AAD patients and 406 healthy control subjects from continental Italy. Results: Frequency of allele G of MHC2TA was significantly increased among AAD patients (39{\%} alleles), compared with 29{\%} in healthy controls (P = 0.003). Similarly, the frequency of AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a codominant (P = 0.012) and a G-dominant model (P = 0.018). Multivariate logistic regression analysis showed that MHC2TA AG+GG continued to be positively associated with genetic risk for AAD (P = 0.028, odds ratio = 1.72, 95{\%} confidence interval = 1.06-2.78), after correction for DRB1*03- DQA1*0501-DQB1*0201, DRB1*04 (not 0403)-DQA1*0301- DQB1*0302 and DRB1*0403. Similar results were obtained when the number of G alleles was included in the model (P = 0.004; odds ratio = 1.65, 95{\%} confidence interval = 1.17-2.32). Conclusions: Our study provides the first demonstration of the association of the polymorphism of the MHC2TA gene with genetic risk for AAD that appears to be independent from the well-known association with the polymorphism of HLA class II genes.",
author = "Mehran Ghaderi and Giovanni Gambelunghe and Cristina Tortoioli and Annalisa Brozzetti and Ken Jatta and Baback Gharizadeh and {De Bellis}, Annamaria and Giraldi, {Francesca Pecori} and Massimo Terzolo and Corrado Betterle and Alberto Falorni",
year = "2006",
month = "10",
doi = "10.1210/jc.2006-0855",
language = "English",
volume = "91",
pages = "4107--4111",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency

AU - Ghaderi, Mehran

AU - Gambelunghe, Giovanni

AU - Tortoioli, Cristina

AU - Brozzetti, Annalisa

AU - Jatta, Ken

AU - Gharizadeh, Baback

AU - De Bellis, Annamaria

AU - Giraldi, Francesca Pecori

AU - Terzolo, Massimo

AU - Betterle, Corrado

AU - Falorni, Alberto

PY - 2006/10

Y1 - 2006/10

N2 - Context: The polymorphism of class II HLA genes modulates the genetic risk for several endocrine autoimmune diseases. The constitutive class II expression on antigen-presenting cells is under the control of the MHC class II transactivator, encoded by the MHC2TA gene, which is mapped to chromosome 16p13. The MHC2TA -168 A→G single nucleotide polymorphism (rs3087456) has been suggested to confer susceptibility to some autoimmune diseases. Design: With the aim of testing whether this MHC2TA single nucleotide polymorphism is independently associated with autoimmune Addison's disease (AAD) and/or modulates the genetic risk conferred by DRB1-DQA1-DQB1 haplotypes, we analyzed DNA samples from 128 AAD patients and 406 healthy control subjects from continental Italy. Results: Frequency of allele G of MHC2TA was significantly increased among AAD patients (39% alleles), compared with 29% in healthy controls (P = 0.003). Similarly, the frequency of AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a codominant (P = 0.012) and a G-dominant model (P = 0.018). Multivariate logistic regression analysis showed that MHC2TA AG+GG continued to be positively associated with genetic risk for AAD (P = 0.028, odds ratio = 1.72, 95% confidence interval = 1.06-2.78), after correction for DRB1*03- DQA1*0501-DQB1*0201, DRB1*04 (not 0403)-DQA1*0301- DQB1*0302 and DRB1*0403. Similar results were obtained when the number of G alleles was included in the model (P = 0.004; odds ratio = 1.65, 95% confidence interval = 1.17-2.32). Conclusions: Our study provides the first demonstration of the association of the polymorphism of the MHC2TA gene with genetic risk for AAD that appears to be independent from the well-known association with the polymorphism of HLA class II genes.

AB - Context: The polymorphism of class II HLA genes modulates the genetic risk for several endocrine autoimmune diseases. The constitutive class II expression on antigen-presenting cells is under the control of the MHC class II transactivator, encoded by the MHC2TA gene, which is mapped to chromosome 16p13. The MHC2TA -168 A→G single nucleotide polymorphism (rs3087456) has been suggested to confer susceptibility to some autoimmune diseases. Design: With the aim of testing whether this MHC2TA single nucleotide polymorphism is independently associated with autoimmune Addison's disease (AAD) and/or modulates the genetic risk conferred by DRB1-DQA1-DQB1 haplotypes, we analyzed DNA samples from 128 AAD patients and 406 healthy control subjects from continental Italy. Results: Frequency of allele G of MHC2TA was significantly increased among AAD patients (39% alleles), compared with 29% in healthy controls (P = 0.003). Similarly, the frequency of AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a codominant (P = 0.012) and a G-dominant model (P = 0.018). Multivariate logistic regression analysis showed that MHC2TA AG+GG continued to be positively associated with genetic risk for AAD (P = 0.028, odds ratio = 1.72, 95% confidence interval = 1.06-2.78), after correction for DRB1*03- DQA1*0501-DQB1*0201, DRB1*04 (not 0403)-DQA1*0301- DQB1*0302 and DRB1*0403. Similar results were obtained when the number of G alleles was included in the model (P = 0.004; odds ratio = 1.65, 95% confidence interval = 1.17-2.32). Conclusions: Our study provides the first demonstration of the association of the polymorphism of the MHC2TA gene with genetic risk for AAD that appears to be independent from the well-known association with the polymorphism of HLA class II genes.

UR - http://www.scopus.com/inward/record.url?scp=33749540401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749540401&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-0855

DO - 10.1210/jc.2006-0855

M3 - Article

C2 - 16849401

AN - SCOPUS:33749540401

VL - 91

SP - 4107

EP - 4111

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -